WO2026002271 - ANTIBODY FORMULATION FOR COAGULATION FACTOR XI AND/OR ACTIVATED FORM FACTOR XIA
National phase entry is expected:
Publication Number
WO/2026/002271
Publication Date
02.01.2026
International Application No.
PCT/CN2025/105213
International Filing Date
28.06.2025
Title **
[English]
ANTIBODY FORMULATION FOR COAGULATION FACTOR XI AND/OR ACTIVATED FORM FACTOR XIA
[French]
FORMULATION D'ANTICORPS POUR LE FACTEUR XI DE COAGULATION ET/OU LE FACTEUR XIA SOUS FORME ACTIVÉE
[Chinese]
抗凝血因子XI和/或其活化形式因子XIa的抗体制剂
Applicants **
GAN & LEE PHARMACEUTICALS CO., LTD.
Inventors
JIAO, Jiao
LIU, Yaohui
QIN, Han
WANG, Xi
WANG, Jiaxing
FU, Shiying
CHEN, Ying
XU, Xuexue
WANG, Jiao
XIE, Yindan
JIANG, Yating
LU, Tengfei
WANG, Lijuan
Priority Data
202410863807.1
29.06.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2445 | |
| EPO | Filing, Examination, Granting | 20454 | |
| Japan | Filing, Examination, Granting | 2616 | |
| South Korea | Filing, Examination, Granting | 3125 | |
| USA | Filing, Examination, Granting | 8540 |
Total:
37,180
Contact Us
Abstract[English]
The present invention relates to the field of pharmaceutical formulations, and in particular, to a liquid pharmaceutical formulation comprising an anti-FXI/FXIa antibody and an antigen-binding fragment thereof, and use thereof as a medicament.[French]
La présente invention concerne le domaine des formulations pharmaceutiques, et en particulier, une formulation pharmaceutique liquide comprenant un anticorps anti-FXI/FXIa et un fragment de liaison à l'antigène de celui-ci, et son utilisation en tant que médicament.[Chinese]
本发明涉及药物制剂领域，具体涉及一种包含抗FXI/FXIa抗体及其抗原结合片段的液体药物制剂，以及其作为药物的用途。